Korro Bio (KRRO) Cash & Equivalents (2018 - 2026)

Korro Bio (KRRO) has 9 years of Cash & Equivalents data on file, last reported at $61.7 million in Q1 2026.

• Quarterly Cash & Equivalents fell 3.81% year-over-year to $61.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.7 million (down 3.81% YoY) and the FY2025 annual result came in at $21.8 million, down 60.78% from the prior year.
• Cash & Equivalents grew to $61.7 million in Q1 2026, from $21.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $166.2 million in Q4 2023 to a low of $21.8 million in Q4 2025.
• A 5-year average of $59.7 million and a median of $43.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 70.55% — and 2023, when it surged 357.3%.
• Tracing KRRO's Cash & Equivalents over 5 years: stood at $36.3 million in 2022, then surged by 357.3% to $166.2 million in 2023, then sank by 66.51% to $55.6 million in 2024, then sank by 60.78% to $21.8 million in 2025, then surged by 182.7% to $61.7 million in 2026.
• The last three Cash & Equivalents figures came in at $61.7 million (Q1 2026), $21.8 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.